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A B S T R A C T
Objective: The C3435T, amajor allelic variant of the ABCB1 gene, is proposed to play a crucial role in drug-
resistance in epilepsy. The C/C genotype carriers reportedly are at higher risk of pharmacoresistance to
AEDs, but only in some studies. The hypothesis of the C-variant associated risk and resistance to
antiepileptic drugs (AEDs) has been hampered by conﬂicting results from inadequate power in case–
control studies. To assess the role of C3435T polymorphism in drug-resistance in epilepsy, a systematic
review and meta-analysis was conducted.
Methods: Databases were obtained from the Cochrane Library, MEDLINE, EMBASE, major American and
European conference abstracts, andwww.google.my for genetic association studies up to February 2010.
All the case–control association studies evaluating the role of ABCB1 C3435T in pharmacoresistance to
AEDs were identiﬁed. The new deﬁnition of treatment outcome from International League Against
Epilepsy (ILAE) was used for including studies for sub-analysis. To measure the strength of genetic
association for the gene variant, the odds ratios (ORs)with 95% conﬁdence intervals (CIs) were calculated
using models of both ﬁxed- and random-effects for comparisons of the alleles and genotypes with co-
dominant (C/C vs. T/T, C/T vs. T/T), dominant (C/C + C/T vs. T/T), and recessive (C/C vs. C/T + T/T)models in
overall and in ethnicity subgroups. The 19 studies were selected for the next sub-analysis based on the
new deﬁnition of drug-responsiveness and drug-resistance from ILAE. The same analysis was also
performed for treatment outcome and ethnicity subgroups.
Results: A total of 22 association studies including 3231 (47.8%) drug-resistant patients and 3524 (52.2%)
drug-responsive patients or healthy controls (genotyped for C3435T) were pooled in this meta-analysis.
The allelic association of ABCB1 C3435T with risk of drug-resistance was not signiﬁcant under ﬁxed-
effects model, 1.06 (95% CI 0.98–1.14, p = 0.12) and random-effects model, 1.10 (0.93–1.30, p = 0.28) in
overall and in the subgroup analysis by ethnicity. Similar results were also obtained for all genetic
models in the stratiﬁed analyses by new deﬁnition of drug-resistance by ILAE and ethnicity subgroups.
There was no publication bias.
Conclusion: We failed to show an association between the ABCB1 C3435T polymorphism and the risk of
drug-resistance suggesting a revision in contribution of this polymorphism in the multi-drug
transporters hypothesis of pharmacoresistance to AEDs in epilepsy.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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journal homepage: www.e lsev ier .com/ locate /yse izEpilepsy is a complex disease characterized by a predisposition
to recurrent unprovoked seizures.1 Despite treatment with
antiepileptic drugs (AEDs), about one-third of newly treated
patients do not respond adequately to medications, making
pharmacoresistance a major problem in the control of this
condition.2 Recent studies have investigated the association* Corresponding author.
E-mail address: batoolsadat@yahoo.com (B.S. Haerian).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.05.004between over-expression of efﬂux transporters and excess efﬂux
of AEDs across the blood–brain barrier (BBB) thereby leading to
drug-resistant epilepsy.3 P-glycoprotein (P-gp) was the ﬁrst
discovered human ABC transporter more than 30 years ago in
drug-resistance ovarian cells obtained from Chinese hamsters.4
P-gp is the most studied protein among the ATP-binding cassette
(ABC) efﬂux transporters. This transmembrane transporter is the
product of the ABC subfamily B member 1 transporter (ABCB1)
gene, encoded by ABC subfamily B member 1 transporter (ABCB1)
gene and located at the endothelial cells of the BBB.5 The level of P-vier Ltd. All rights reserved.
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Inter-individual variability of P-gp activity may affect blood levels
and drug distribution to the speciﬁc target compartment.6 The
ABCB1 gene is highly polymorphic and more than 50 variants
reside in the coding region which can possibly cause altered
function. The C3435T polymorphism is one of the most common
polymorphisms in the ABCB1 gene.7
There appears to be a possible link between the ABCB1 C3435T
polymorphism and drug-resistance epilepsy but results from
various studies indicate that this is controversial. The ﬁrst
pharmacogenetic study on this matter suggested a strong and
signiﬁcant association (P = 0.006) between the C/C genotype in the
ABCB1 C3435T polymorphism and drug-resistant epilepsy.8
Following that study, 21 replication studies were conducted to
evaluate this hypothesis, but only nine conﬁrmed the results of the
ﬁrst report (Table 2). It is unclear why these reports have found
such contradictory results. How can such conﬂicting results be
interpreted? Is there any obvious effect of C3435T polymorphism
on response to AEDs even if the phenotypes are almost the same?
Two meta-analyses of three and eleven association studies
published in 2007 and 2008, respectively did not conﬁrm whether
the C3435T in the ABCB1 gene contributes to the risk of drug-
resistance in epilepsy patients and certain ethnic subgroups.9,10
Therefore, to overcome the limitations of the individual studies
and reliably assess the hypothesized ABCB1 C3435T polymor-
phism relationship with the risk of drug-resistance in epilepsy on
the basis of the existing data, we provided pooled estimates using
both ﬁxed- and random-effects models in overall, the Asian and
Caucasian populations and deﬁnition of treatment outcome using
all genetic model analysis.
1. Method
1.1. Search strategy and selection
All articles that examined the ABCB1 C3435T association with
drug-resistance in epilepsy were identiﬁed. Databases were
obtained from MEDLINE, EMBASE, as well as the Cochrane
Database of Systematic Reviews, major American and European
conference abstracts, and www.google.com and all relevant
studies were compiled up to February 2010. Non-English language
publications were excluded. Additionally, we hand searched the
reference lists of retrieved full-text articles. MESH terms used
included ‘‘EPILEPSY’’, ‘‘POLYMORPHISM’’, ‘‘ABCB1’’, ‘‘C3435T’’,
‘‘DRUG-RESISTANT’’, ‘‘DRUG-RESPONSIVENESS’’, ‘‘ANTIEPILEPTIC
DRUGS’’, and ‘‘ANTICONVULSANT DRUGS’’ (including ‘‘MONO-
THERAPY’’ and ‘‘POLYTHERAPY’’). Two reviewer independently
assessed titles and abstracts of electronic searches, obtaining the
full articles to assess for relevance where necessary.
1.2. Data extraction
For primary selection of the studies, all articles published till
February 2010, were considered. All selected articles were
examined for their appropriateness by two independent reviewers
using an extraction template. Disagreements were documented
and resolved by discussion with a third author. The case–control
genetic association studies included in this meta-analysis had to
meet the following criteria: (a) AED treatment of patients and
compliance; (b) data on genotype distributions were available for
both case and control groups; (c) genotype distribution of the
control subjects conformed to the Hardy–Weinberg equilibrium;
and (d) clear treatment outcome of either resistant or responsive to
AEDs. Information on name of the ﬁrst author, year of publication,
country, journal, ethnic origin of the studied population, sample
size, deﬁnition of drug-resistance and drug responsiveness, thetypes of epilepsy syndromes and AED treatment, genotyping
methods, genotype and allele distributions, and conﬁrmation of
the diagnosis were abstracted. Genotype distributions reported in
percentages were converted to actual numbers. If allele frequen-
cies were not given, they were calculated from the corresponding
genotype distributions. The control group was either drug-
responsive epilepsy patients receiving AEDs or healthy people.
In each study, if both drug-responsive patients and control data
were available, we used drug-responsive patients’ data for
analyses. The phenotype deﬁnition of treatment outcome in each
study was assessed according to the new three categories from the
International League Against Epilepsy (ILAE): (1) drug-responsive-
ness as complete seizure freedom for at least one year; (2) drug-
resistant as failure of two tolerated and appropriately chosen and
used AED schedules (whether as monotherapies or in combina-
tion) to achieve sustained seizure freedom; and (3) undeter-
mined.11 The consistent studies with outcome categories either 1
and 2 or 3 were classiﬁed as group one and two, respectively.
1.3. Statistical analysis
The meta-analysis was performed to examine the overall
association for allelic (C vs. T) and genotype geneticmodels (C/C vs.
T/T and C/T vs. T/T, C/C + C/T vs. T/T, and C/C vs. C/T + T/T, assuming
co-dominant, dominant, and recessive effects) of the 3435C allele
and the risk of resistance to AEDs. Deviation of Hardy–Weinberg
equilibrium (HWE) was examined by x2 tests. The per-allele odds
ratio (OR) of the rare allele (3435T) as well as the corresponding
95% conﬁdence intervals (CI) and p valuewere calculated as using a
comparative two group outcomes statistics to compare drug-
resistant and drug-responsive patients. Fixed-effects summary
measures were calculated as inverse-variance–weighted average
of the log OR if there was no heterogeneity (p > 0.10) and random-
effects where substantial heterogeneity (p < 0.10) exist. To
measure the strength of genetic association, we used the I2 test
to assess the proportion of statistical heterogeneity and the Q-
statistic test with a p < 0.10 to deﬁne a signiﬁcant degree of
heterogeneity. A sensitivity analysis was carried out by excluding
each study in turn to investigate the extent to which they
contributed to the heterogeneity. Subsidiary analyses including
subgroup analyses were performed to evaluate the effects of either
ethnicity in overall of studies for allelic model or deﬁnition of
treatment outcome and ethnicity in overall and subgroups under
all genetic models. Ethnic group was deﬁned as Asian and
Caucasians. The new deﬁnition of treatment outcome from ILAE
was used for sub-analysis of both subgroups one and two and
ethnicity in the ﬁrst subgroup. All probability values are 2-sided,
and values of P < 0.05 were considered statistically signiﬁcant. The
evidence of publication bias was assessed by visual funnel plot
inspection and Egger’s test. Statistical analyses were performed
using validated Meta-analysis Made Easy (MIX) version 1.7.12
2. Results
2.1. Study characteristics
The initial search with the keywords and the subject terms
identiﬁed 22 publications that met the inclusion criteria and were
eligible for review. Out of the 22 studies, ninewere positive studies
amongwhich the carriers homozygous for the 3435T allele in three
studies were signiﬁcantly higher in the drug-resistant than in the
drug-responsive patients. Among the 22 included studies, there
was considerable diversity between ethnic groups. Fourteen
articles represented studies with the Asian populations,14–27 while
seven were carried out in European descent populations.8,28–33
Patients were recruited from Egypt (one),19 Australia (one),30
B.S. Haerian et al. / Seizure 19 (2010) 339–346 341China (ﬁve studies),14,15,18,21,25 Croatia (one),28 Germany (one),33
India (two studies),26,27 Ireland (one),15 Japan (one),17 Korea (three
studies),15,16,24 Scotland (one),31 Turkey (two studies),22,23 and
United Kingdom (two studies).8,29 In one multi-centre cooperation
study, subjects were collected from Australia, Hong Kong and
Scotland.13 We divided this study into three sub-studies for meta-
analysis. Hence, the total number of studies for meta-analysis
could be considered to be 24 instead of 22 for analyses.
Characteristics of the included studies are presented in Table 1.
The included studies provided a total of 6755 subjects, 3231
(47.8%) drug-resistant patients and 3524 (52.2%) drug-responsive
epilepsy patients or healthy controls. The median number of
sample size was 288 (range, 45–609). The genotype and allele
distributions of ABCB1 C3435T in the studies are shown in Table 2.
The ABCB1 C3435T polymorphism was found to occur in
frequencies consistent with HWE in the drug-resistant and
drug-responsive epilepsy patients or healthy populations of the
published studies.
Although the basic study design was the same, a wide variety of
epilepsy syndromes, AED types, and deﬁnition of treatment
outcomes were used. From 24 studies, 19 studies were compatible
with the new outcome categories from ILAE, 12 performed in the
Asian populations13–16,18,20–21,23–27 and seven in the Caucasian
populations8,13,28–31 (Table 4), while ﬁve studies were incompati-
ble17,19,22,32–33 (Table 5).Table 1
Characteristics of the analyzed studies of ABCB1 C3435T polymorphism in relation to




R NR C NR
Positive studies (n=9)
1 Siddiqui et al. 2003 UK 200 115 200 >4 seizures in yea
2 Hajnsek et al. 2004 Croatia 30 30 - As Seddique et al.
3 Soranzo et al. 2004 UK 280 136 - As Seddique et al.
4 Hung et al. 2005 Taiwan 108 223 287 >10 seizures in ye
5 Seo et al.** 2006 Japan 126 84 - 1 seizure in mon
6 Ebid et al.** 2007 Egypt 63 37 50 Seizure in 6 month
7 Hung et al. 2007 Taiwan 114 213 287 >10 seizures in ye
8 Kwan et al. 2007 China 221 297 179 1 seizure in mon
9 Kwan et al. 2009 China 194 270 - 1 seizure in mon
Negative studies (n=15)
10 Tan et al. 2004 Australia 401 208 - As Seddique et al.
11 Sills et al. 2005 Scotland 230 170 - All patients with a
seizures
12 Kim et al. 2006 Korea 59 101 212 As Seddique et al.
13 Kim et al. 2006 Korea 99 100 - As Seddique et al.
14 Chen et al. 2007 China 50 164 - As Seddique et al.
15 Shahwan et al.** 2007 Ireland 122 233 - <50% seizure redu
in year
16 Dericioglu et al.** 2008 Turkey 89 - 100 Resective brain su
(at least 1 seizure/
17 Ozgon et al. 2008 Turkey 44 53 174 4 seizures in 6 m
18 Kim et al. 2009 Korea 198 193 - As Seddique et al.
19 Lakhan et al. 2009 India 94 231 97 As Seddique et al.
20* Szoeke et al. 2009 Combined 208 334 - Seizure in year
20-1 Szoeke et al. 2009 Scotland 133 152 - Seizure in year
20-2 Szoeke et al. 2009 Australia 64 148 - Seizure in year
20-3 Szoeke et al. 2009 Hong Kong 11 34 - Seizure in year
21 Ufer et al.** 2009 Germany 188 103 242 Receiving any seco
drug due to non-re
or adverse reaction
course of the initia
treatment
22 Vahab et al. 2009 India 113 129 - <6 month termina
remission
* Data of the combined cohort study in number 20 is divided into three studies by p
** Incompatible with new ILAE deﬁnition of drug-resistance11.
Abbreviations: CBZ, carbamazepine; PHT, phenytoin; R, drug-responsive; NR, drug-resista
ILAE, International League Against Epilepsy.2.2. Meta-analysis
In a pooled analysis of 24 studies, no signiﬁcant allelic
association was recorded under either ﬁxed-effects model 1.06
(95% CI 0.98–1.14, p = 0.12) or random-effects model, 1.10 (0.93–
1.30, p = 0.28) indicating that the C allele is not associated with the
risk of resistance to AED in epilepsy as compared to the T allele
(Fig. 1, Table 3). The wide variation in the C allele frequency in
drug-responsive and drug-resistant patients caused high and
signiﬁcant heterogeneity (I2 = 80.7%, p < 0.0001). A sensitivity
analysis which excluded each study in turn, demonstrated a
decrease of the pooledOR from1.06 to 0.93 but still non-signiﬁcant
(95% CI 0.86–1.01, p = 0.09). This heterogeneity was contributed
mainly by the six positive studies8,14,17,19,20,28 among which the
effect of two studies14,19 was higher. Removal of these six studies
from meta-analysis gave 24.48% (p = 0.17) heterogeneity and
showed that they have the highest effect on ABCB1 C3435T allelic
associationwith the risk of resistance to AEDs. The ethnicity-based
subgroup meta-analysis examining allelic model, also showed no
signiﬁcant association in the either Asian or Caucasian populations
(Table 3).
In a comparable genotype data, the association of all genetic
models with drug-resistance was not statistically signiﬁcant.
Subsidiary analyses of ethnicity in the 15 and nine studies from










r >1 year seizure freedom Various Various C/C 8
As Seddique et al. Various Various T/T 28
As Seddique et al. Various Various C/C 29
ar >2 years seizure freedom Various Various C/C 14
th >1 year seizure freedom Various CBZ T/T 17
s >6 months seizure freedom Various PHT C/C 19
ar >2 years seizure freedom Various Various C/C 20
th >1 year seizure freedom Various Various T/T 21
th >1 year seizure freedom Various Various C/C 25
As Seddique et al. Various Various - 30
ny >1 year seizure freedom Various Various - 31
As Seddique et al. Various Various - 15
As Seddique et al. Various Various - 16
As Seddique et al. Various Various - 18
ction >1 year seizure freedom
or 50% seizure reduction
Various Various - 32
rgery
month)
Healthy volunteers SPE or CPE Various - 22
onths >1 year seizure freedom Various CBZ - 23
As Seddique et al. Various Various - 24
As Seddique et al. Various Various - 26
>1 year seizure freedom Various Various - 13
>1 year seizure freedom Various Various - 13
>1 year seizure freedom Various Various - 13







Various Various - 33
l >1 year seizure freedom Various Various - 27
opulation (20-1, 20-2, and 20-3).
nce; C, control; SPE, symptomatic partial epilepsy; CPE, cryptogenic partial epilepsy;
Table 2
Distribution of ABCB1 C3435T genotypes and allele frequencies among drug-resistance and drug-responsive epilepsy patients.
Author Year Population Distribution of ABCB1 genotypes Distribution of ABCB1 alleles Ref.
C/C C/T T/T C T
NR R NR R NR R NR R NR R
Positive studies (n=9)
1 Siddiqui et al. 2003 UK 55 18 106 63 39 34 216 99 184 131 8
2 Hajnsek et al. 2004 Croatia 12 4 14 15 4 11 38 23 22 37 28
3 Soranzo et al. 2004 UK 73 20 145 80 62 36 291 120 269 152 29
4 Hung et al. 2005 Taiwan 47 31 46 118 15 74 140 180 76 266 14
5 Seo et al.** 2006 Japan 34 36 58 34 34 14 126 106 126 62 17
6 Ebid et al.** 2007 Egypt 35 5 24 17 4 15 94 27 32 47 19
7 Hung et al. 2007 Taiwan 40 39 55 107 19 67 135 185 93 241 20
8 Kwan et al. 2007 China 80 114 104 161 37 22 264 389 178 205 21
9 Kwan et al. 2009 China 71 101 94 148 29 21 236 350 152 190 25
Negative studies (n=15)
10 Tan et al. 2004 Australia 75 37 193 115 133 56 343 189 459 227 30
11 Sills et al. 2005 Scotland 41 32 112 82 77 56 194 146 266 194 31
12 Kim et al. 2006 Korea 19 48 27 30 13 23 65 126 53 76 15
13 Kim et al. 2006 Korea 47 45 46 48 6 7 140 138 58 62 16
14 Chen et al. 2007 China 15 63 25 79 10 22 55 205 45 123 18
15 Shahwan et al.** 2007 Ireland 20 37 64 119 38 77 104 193 140 273 32
16 Dericioglu et al.** 2008 Turkey 26 25 34 49 29 26 86 99 92 101 22
17 Ozgon et al. 2008 Turkey 13 16 26 29 5 8 52 61 36 45 23
18 Kim et al. 2009 Korea 73 81 97 90 28 22 243 252 153 134 24
19 Lakhan et al. 2009 India 9 38 52 104 33 89 70 180 118 282 26
20 Szoeke et al. 2009 Combined 42 81 104 159 62 94 188 321 228 347 13
20-1 Szoeke et al.* 2009 Scotland 20 34 69 72 44 46 109 140 157 164 13
20-2 Szoeke et al.* 2009 Australia 21 34 27 67 16 47 69 135 59 161 13
20-3 Szoeke et al.* 2009 Hong Kong 1 13 8 20 2 1 10 46 12 22 13
21 Ufer et al.** 2009 Germany 44 20 85 46 59 37 173 86 203 120 33
22 Vahab et al. 2009 India 3 4 61 82 49 43 67 90 159 168 27
* Data of the combined cohort study in number 20 is divided into three studies by population (20-1, 20-2, and 20-3).
** Incompatible with new ILAE deﬁnition of drug-resistance11.
Abbreviations: R, drug-responsive; NR, drug-resistance; C, control; ILAE, International League Against Epilepsy.
B.S. Haerian et al. / Seizure 19 (2010) 339–346342associations in all genetic models. However, the risk of drug-
resistance in the Caucasian population for the allelic model
(p = 0.10) and co-dominant (C/C vs. T/T: p = 0.10), dominant
(p = 0.38), and recessive (p = 0.09) effects of the ABCB1 C3435T
was greater than in Asians (p = 0.78, p = 0.91, p = 0.93, and p = 0.68,
respectively). A wide range of heterogeneity (0–85.6%) was
observed among the studies in both the Asian and Caucasian
populations. Unlike the co-dominant (C/T vs. T/T) and dominant
genetic models in the Caucasians (p = 0.50 and p = 0.12, respec-
tively), the heterogeneity in the rest was signiﬁcance (Table 3).Table 3
Distribution of ABCB1 C3435T genotypes and allele frequencies among (n=3231) drug-
Twenty-four studies included in this analysis, 15 Asians13–27 and nine Caucasians8,13,2
Comparison Population Allele/genotype (N) Fixed-effects
NR R or C p
C vs. T Total 6462 7048 0.12
Asian 3166 4458 0.74
Caucasian 3296 2590 0.05
C/C vs. T/T Total 1659 1749 0.19
Asian 826 1113 0.88
Caucasian 833 636 0.04
C/T vs. T/T Total 2357 2629 0.60
Asian 1070 1570 0.29
Caucasian 1287 1059 0.78
(C/C+C/T) vs. T/T Total 3231 3524 0.87
Asian 1583 2229 0.44
Caucasian 1648 1295 0.34
C/C vs. (C/T +T/T) Total 3231 3524 0.03
Asian 1583 2229 0.34
Caucasian 1648 1295 0.02
Abbreviations: R, drug-responsive; NR, drug-resistance; C, control; ILAE, International LThe stratiﬁed analysis using the new deﬁnition of ILAE11 for
treatment outcomes was performed for the 19 compatible
(Table 4) and ﬁve incompatible studies (Table 5). The subsidiary
analysis based on this new deﬁnition of treatment outcomes and
ethnicity in the compatible and incompatible studies did not show
any signiﬁcant association under all genetic models (Table 4). The
range of heterogeneity in the compatible group was wide (14.3–
83.3%) and signiﬁcant, except of Caucasians under co-dominant (C/
T vs. T/T) (p = 0.32) and dominant (p = 0.05) models. Similarly, the
incompatible studies showed a wide range of heterogeneity (58.8–resistance and drug-responsive (n=3524) epilepsy patients based on the ethnicity.
8–33.
model Random-effects model I2 (%) p
OR (95% CI) p OR (95% CI)
1.06 (0.98–1.14) 0.28 1.10 (0.93–1.30) 80.7 0.00
1.02 (0.92–1.12) 0.78 1.04 (0.80–1.35) 85.6 0.00
1.11 (1.00–1.24) 0.10 1.16 (0.97–1.39) 61.4 0.00
1.11 (0.95–1.29) 0.36 1.19 (0.82–1.71) 79.9 0.00
0.98 (0.79–1.22) 0.91 1.03 (0.58–1.85) 84.7 0.00
1.26 (1.01–1.58) 0.10 1.37 (0.94–1.98) 61.3 0.00
0.97 (0.85–1.10) 0.97 1.00 (0.82–1.21) 52.3 0.00
0.90 (0.75–1.09) 0.75 0.95 (0.68–1.32) 65.0 0.00
1.02 (0.86–1.22) 0.78 1.02 (0.86–1.22) 0 0.50
1.01 (0.89–1.14) 0.64 1.06 (0.84–1.34) 69.9 0.00
0.93 (0.78–1.11) 0.93 0.98 (0.66–1.45) 77.6 0.00
1.08 (0.91–1.28) 0.30 1.12 (0.90–1.40) 37.0 0.12
1.14 (1.01–1.28) 0.21 1.17 (0.91–1.51) 75.5 0.00
1.07 (0.93–1.23) 0.68 1.08 (0.75–1.56) 81.3 0.00
1.25 (1.03–1.53) 0.09 1.30 (0.96–1.76) 54.1 0.03
eague Against Epilepsy.
Fig. 1. Results of the published studies of the association between ABCB1 C3435T polymorphism and drug-resistance in epilepsy. Areas of squares of individual studies are
inversely proportional to the variances of the log ORs and the horizontal lines represent 95% CI estimating the outcome of the C allele against the T allele. The study of Szoeke
et al. is divided into three sub-studies for Scotland (a), Australia (b), and Hong Kong (c).
B.S. Haerian et al. / Seizure 19 (2010) 339–346 34394.2%) and signiﬁcant. The funnel plot for C vs. T was basically
symmetric and Egger’s test did not indicate statistically signiﬁcant
asymmetry of the plot [Intercept = 1.54, 95% CI (1.96–5.04,
p = 0.37)], suggesting no evidence of publication bias.
3. Discussion
It was hypothesized that the ABCB1 C3435T polymorphism is
related with the risk of resistance to AEDs in epilepsy. Siddiqui
et al. (2003) for the ﬁrst time examined whether C3435T
polymorphism was associated with resistance to AEDs in the
Caucasians with epilepsy. The frequency of the C/C genotype
among drug-resistant patients was signiﬁcantly higher than in
responsive patients (P = 0.006).8 Zimprich et al. (2004) conﬁrmed
the results of the original report (p = 0.035),34 but the outcome of
the study of Tan et al. (2004) with the exact replication of the ﬁrst
study and almost twice the sample size in the Caucasians wasnegative.30 Similarly, a comprehensive genome wide approach35
and also a combined cohort study in the Scottish, Australian, and
Hong Kong populations, failed to conﬁrm the original ﬁndings.13 In
total, 22 studies attempted to examine this hypothesis in epilepsy,
but only nine found signiﬁcant association in which three reported
that the T/T genotype was more frequent in drug-resistant
patients. There have been also two meta-analysis studies of the
association of ABCB1 C3435T with drug-resistance. The ﬁrst report
included three studies performed in 1073 Caucasians patients with
the same deﬁnition of drug-responsiveness and drug-resistance9
and the second one included 11 studies involving 3371 patients
with different ethnicities and deﬁnition of drug-responsiveness
and drug-resistance.10 Neither studies conﬁrmed this association
and stratiﬁcation of ethnic subgroups in the second meta-analysis
also provided no further evidence.
The ﬁndings of the present meta-analysis indicate that neither
the C allele nor the T allele carriers of the ABCB1 C3435T
Table 5
Distribution of ABCB1 C3435T genotypes and allele frequencies among drug-resistance (n=588) and drug-responsive (n=557) epilepsy patients in the incompatible studies
with the new deﬁnition of ILAE. Seven studies included in this analysis, ﬁve Asians17,19,22 and two Caucasians32–33.
Comparison Population Allele/genotype (N) Fixed-effects model Random-effects model I2 (%) p
NR R or C p OR (95% CI) p OR (95% CI)
C vs. T Total 1176 1114 0.39 1.08 (0.91–1.28) 0.42 1.24 (0.74–2.07) 88.2 0.00
Asian 556 442 0.77 1.04 (0.80–1.34) 0.56 1.38 (0.46–4.11) 94.0 0.00
C/C vs. T/T Total 323 292 0.58 1.10 (0.78–1.56) 0.42 1.45 (0.58–3.63) 84.6 0.00
Asian 162 121 0.91 0.97 (0.58–1.62) 0.51 1.90 (0.28–13.04) 92.1 0.00
C/T vs. T/T Total 429 434 0.88 1.02 (0.76–1.36) 0.79 1.06 (0.66–1.72) 58.8 0.04
Asian 183 155 0.59 0.88(0.55–1.40) 0.78 1.16 (0.40–3.35) 77.9 0.01
(C/C+C/T) vs. T/T Total 588 557 0.71 1.05 (0.80–1.38) 0.56 1.20 (0.65–2.23) 78.5 0.00
Asian 278 221 0.68 0.91 (0.59–1.41) 0.61 1.43 (0.36–5.70) 88.8 0.00
C/C vs. (C/T +T/T) Total 588 557 0.55 1.09 (0.82–1.46) 0.43 1.32 (0.67–2.60) 80.9 0.00
Asian 278 221 0.83 1.04 (0.70–1.56) 0.51 1.58 (0.41–6.15) 90.3 0.00
Abbreviations: R, drug-responsive; NR, drug-resistance; C, control; ILAE, International League Against Epilepsy.
Table 4
Distribution of ABCB1 C3435T genotypes and allele frequencies among drug-resistance (n=2643) and drug-responsive (n=2967) epilepsy patients in the compatible studies
with the new deﬁnition of ILAE. Nineteen studies included in this analysis, 12 Asians13–16,18,20,21,23–27 and seven Caucasians13,28–31.
Comparison Population Allele/genotype (N) Fixed-effects model Random-effects model I2 (%) p
NR R or C p OR (95% CI) p OR (95% CI)
C vs. T Total 5286 5934 0.18 1.05 (0.97–1.14) 0.44 1.07 (0.90–1.28) 78.9 0.00
Asian 2610 4016 0.81 1.01 (0.91–1.12) 0.93 0.99 (0.76–1.28) 82.7 0.00
Caucasian 2676 1918 0.07 1.12 (0.99–1.26) 0.14 1.19 (0.94–1.51) 70.6 0.00
C/C vs. T/T Total 1336 1457 0.24 1.11 (0.93–1.32) 0.54 1.14 (0.76–1.71) 79.7 0.00
Asian 664 992 0.91 0.99 (0.78–1.25) 0.79 0.92 (0.49–1.71) 83.3 0.00
Caucasian 672 465 0.06 1.27 (0.99–1.64) 0.14 1.45 (0.89–2.37) 70.6 0.00
C/T vs. T/T Total 2786 3063 0.51 0.95 (0.83–1.10) 0.88 0.98 (0.79–1.22) 53.1 0.00
Asian 887 1415 0.36 0.91 (0.74–1.11) 0.67 0.93 (0.65–1.32) 64.5 0.00
Caucasian 1041 780 0.99 1.00 (0.82–1.22) 0.90 1.01 (0.81–1.26) 14.3 0.32
(C/C+C/T) vs. T/T Total 3819 4081 1.00 1.00 (0.87–1.14) 0.80 1.03 (0.80–1.34) 68.9 0.00
Asian 1305 2008 0.51 0.94 (0.78–1.14) 0.72 0.93 (0.62–1.40) 75.3 0.00
Caucasian 1338 959 0.52 1.06 (0.88–1.29) 0.37 1.14 (0.85–1.52) 51.8 0.05
C/C vs. (C/T +T/T) Total 3819 4081 0.04 1.15 (1.01–1.31) 0.31 1.15 (0.87–1.52) 75.3 0.00
Asian 1305 2008 0.35 1.08 (0.92–1.27) 0.93 1.02 (0.69–1.50) 79.7 0.00
Caucasian 1338 959 0.02 1.29 (1.03–1.60) 0.11 1.37 (0.93–2.00) 64.7 0.00
Abbreviations: R, drug-responsive; NR, drug-resistance; C, control; ILAE, International League Against Epilepsy.
B.S. Haerian et al. / Seizure 19 (2010) 339–346344polymorphism confer signiﬁcant risk to drug-resistance in
epilepsy. Similar results were found for all genotype genetic
models in overall of studies. In the subgroup analysis for the Asian
and the Caucasian populations, none of the genetic comparisons
showed a signiﬁcant association. Hence, the substitution of C to T
at position 3435 of the exon 26 of the ABCB1 gene does not effect
on response to AEDs in the epilepsy patients with different
ethnicities. As different deﬁnitions of drug-responsiveness and
drug-resistance in the patients with various ethnicities were
included in the studies, we therefore carried out subgroup meta-
analyses based on the new deﬁnition drug-resistance by the ILAE11
and ethnicity. Subsidiary analyses of the deﬁnition of treatment
outcomes in the 19 included and ﬁve excluded studies aswell as by
ethnicity in the included reports did not show any association
under all genetic models.
The current meta-analysis provides a comprehensive assess-
ment of ABCB1 C3435T variant and drug-resistance risk. Mean-
while ourmeta-analysis does not support an association of C3435T
polymorphism with risk of resistance to AEDs. Compared with the
precious meta-analysis, the present study is much larger, with
almost twice as many as the cases as the earlier meta-analysis.
Furthermore, we assessed not only the association between the
C3435T polymorphism and drug-resistance risk in the consistent
and inconsistent studies with the new deﬁnition of ILAE fortreatment outcome in epilepsy but also for the stratiﬁed subgroup
by ethnicity in the consistent group with ILAE deﬁnition. The non-
concordance in the studies may be explained by ﬁve phenomena:
(i) publication bias which can be caused by false positive results,
found by chance as a result of insufﬁcient sample size and low
statistical power.36,37 The meta-analysis by Bournissen et al
(2008)10 and our results, however, did not indicate signiﬁcant
publication bias. Moreover, sample size of the included 22 genetic
association studies in the current meta-analysis was quite small,
the median being 288. In order to have a power of 80%, it needs a
large sample size or collaboration between multi-centres and
countries38 (20). (ii) Population diversity with different race and
types of seizures and epilepsy syndromes may cause variety in
AEDs type administration, dosage, and treatment duration.39
However, the data of Bournissen et al (2008) and the currentmeta-
analysis showed no evidence that the ABCB1 C3435T polymor-
phism is associatedwith the risk of resistance to AEDs in the Asians
and Caucasians. Furthermore, the data were not sufﬁcient enough
to allow us to undertake further subgroup analyses on speciﬁc
subsets of epilepsy types/syndromes and AEDs type. (iii) Variabili-
ty in the deﬁnitions of treatment outcomes to distinguish drug-
resistance from drug-responsiveness in epilepsy may cause
variations in the results.40 Since, those patients who are classiﬁed
as drug-resistant in some studies may be drug-responsiveness.41
B.S. Haerian et al. / Seizure 19 (2010) 339–346 345Despite of the fact that we have excluded ﬁve studies, there is no
effect on the overall results as well as the results in the Asians and
Caucasian subgroups. Furthermore, a short-term follow-up of
newly diagnosed patients in the cohort studies leads to misclassi-
ﬁcation. The shortest follow-up period used by new deﬁnition of
drug-resistance and drug-responsiveness from ILAE was 12
months,11 while the range of response to AEDs is 2–16 years
(median, 5 years);3 the shortest follow-up periods for both drug-
resistance and drug-responsiveness to AEDs in the 22 included
studies in this meta-analysis was 3 months.(iv) It is not clear
whether some AEDs are substrates of P-gp;42–44 hence justiﬁcation
of the results is difﬁcult. Moreover, the interaction between AEDs
in poly-therapy regimens can inﬂuence the response to AEDs.45 In
this study, because of data limitation; we did not carry out the
stratiﬁcation analyses by AED monotherapy regimens. (v) The
complex gene–gene (epistasis) and/or gene–environment inter-
actions contribute to etiology and response to AEDs in epilepsy.
The marginal effect of each susceptibility gene is small but the
effect of these genes acting through a set of genes and their variants
epistically in the same pathway may be large.46 The discrepant
results may be caused by cross-tabulation of the C3435T
polymorphism with speciﬁc variants either in the ABCB1 gene
or other genes.39 In addition, C3435T might have only marginal
functional signiﬁcance as suggested by Cascorbi.47 Such a variant–
variant interaction may play an important role in gene–disease
associations than individual polymorphism in epilepsy and cause
variety in AED types administration, dosage, and treatment
duration across and within the populations with different
features.39 Further studies in larger and different populations
need to be conducted to examine this hypothesis.
4. Conclusions
The results of this meta-analysis do not provide support for the
association of the ABCB1 C3435T polymorphism with risk of
resistance to AEDs in different races and suggest a revision in
contribution of this polymorphism in the multi-drug transporters
hypothesis of resistance to AEDs in epilepsy.
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